Table 1.

Enrollment of patients in phase I study with long peptide HPV16 E6 and E7

StudyIDAgeFIGO stagePrimary treatmentRecurSecondary treatmentVaccination (n)Clinical statusFollow-up (mo)
1153IBRHLRCHRT4Died9
247IB1RH/RTDRT2Died3
333IIBRT/HTDCH/HT4Died9
442IB2RHD0Died1
559IVCH0
653IIICHRTD4Died11
744IB1RHD1Died1
8322Lost to follow-up1
941IB2RHLRCH/HT/SUR4Died7
1072IIART/HTLRSUR4Died4
11483Died3
1258IIIRTDCH4Died6
1356IB1RH/RTLRSUR3Died4
21458IIBCHRTLRCH5Alive, CR36
1535D3Died2
1636IB1RH/RTLRCHRT4Died4
1748IB2CH/RHLRRT/HT/SUR4Died9
1844CHRT4Died4
190
2039CH/RT/HT4Died2
2148IIACHRTLRCH2Died2
2234IB1RHLRCH4Died3
2335IIIBCH/RT/HTDCHRT2Died3
2444IVCH3Died2
2544IA2RHDCH0Died0
2644IARHLRRT4Died2
2760IB1RHDCH4Alive, stable26
2839RHDCHRT3Lost to follow-up2
2956IVCHLRRT4Died2
3048IB1RH/RTDRT4Alive, stable24
3151IBRHLRCHRT4Died3
3257IBRH/RTDRT4Alive, stable24
33333IB2RH/RTLRRT1Died1
3458IIARH/RTLRRT/HT4Died3
3530IIACHLRCH1Withdrawn0
3648IB1RH/RTLR2Died8
3754IIBCH/RHLRCHRT4Died3
3842IIIBCHRTLRCH4Died7
3941IB1RHLRRT/HT4Died17
4034IIBCH/RHLRRT/HT4Died4
4132IB1RHLRSUR4Alive, stable18
4242IB2CH/RHLRRT/SUR4Alive, stable18
4329IB1RH/RTLRCH4Died5
4443IB2RH/RTLRCH4Died7
45CH0
4649CHRTCH4Died2
4736IIARH/RTLRCH/HT/SUR4Died7
4834IIIBRH/RTDRT4Died8
  • NOTE: Numbers 1 to 13 were vaccinated with 300 μg E6 and E7 each in a combined vaccination (patient group 1), numbers 14 to 32 were vaccinated with 100 μg E6 and 300 μg E7 in a separate vaccine (group 2), and numbers 33 to 48 were vaccinated with 50 μg E6 and E7 each in a separate vaccine (group 3). The stage of the disease is given as the International Federation of Gynecologists and Obstetricians stage. The primary treatment, the localization of the recurrence, the secondary treatment, and the number of vaccinations in the current immunotherapeutic trial are shown. The follow-up time is depicted in months after the first vaccination; however, some of the patients were lost to follow-up after receiving one or more vaccinations. All death was because of progressive disease. From the six patients still alive at least one and half year after the vaccinations (i.e., July 2007), patient 14 is a complete responder. Patients 27, 30, 32, and 41 have received chemotherapy after the vaccinations and have stable disease. Patient 42 received radiotherapy after the immunotherapy and also has stable disease.

    Abbreviations: LR, locoregional; D, distant metastasis; RH, radical hysterectomy; RT, radiotherapy; CH, chemotherapy; CHRT, chemoradiation; HT, hyperthermia; SUR, surgery; FIGO, International Federation of Gynecologists and Obstetricians; CR, complete responder.